Cargando…

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency

BACKGROUND: The development of COPD in subjects with alpha-1 antitrypsin (AAT) deficiency is likely to be influenced by modifier genes. Genome-wide association studies and integrative genomics approaches in COPD have demonstrated significant associations with SNPs in the chromosome 15q region that i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Woo Jin, Wood, Alice M, Barker, Alan F, Brantly, Mark L, Campbell, Edward J, Eden, Edward, McElvaney, Gerard, Rennard, Stephen I, Sandhaus, Robert A, Stocks, James M, Stoller, James K, Strange, Charlie, Turino, Gerard, Silverman, Edwin K, Stockley, Robert A, DeMeo, Dawn L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306733/ https://www.ncbi.nlm.nih.gov/pubmed/22356581 http://dx.doi.org/10.1186/1465-9921-13-16

Ejemplares similares

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Pharmacokinetic comparability of Prolastin(®)-C to Prolastin(® )in alpha(1)-antitrypsin deficiency: a randomized study
por: Stocks, James M, et al.
Publicado: (2010)

Detection of alpha-1 antitrypsin deficiency: the past, present and future
por: Brantly, Mark, et al.
Publicado: (2020)

Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency
por: Sandhaus, Robert A, et al.
Publicado: (2020)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

IREB2, CHRNA5, CHRNA3, FAM13A & hedgehog interacting protein genes polymorphisms & risk of chronic obstructive pulmonary disease in Tatar population from Russia
por: Korytina, Gulnaz Faritovna, et al.
Publicado: (2016)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

An analysis of the degree of concordance among international guidelines regarding alpha-1 antitrypsin deficiency
por: Attaway, Amy, et al.
Publicado: (2019)

Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency
por: Mayer, Annyce S, et al.
Publicado: (2006)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial
por: Campos, Michael A., et al.
Publicado: (2019)

Cystic fibrosis disease severity correlates with plasma levels of desmosine and isodesmosine, biomarkers of elastin degradation
por: Ma, Shuren, et al.
Publicado: (2019)

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.
por: Jundi, Bakr, et al.
Publicado: (2015)

Unique and shared systemic biomarkers for emphysema in Alpha-1 Antitrypsin deficiency and chronic obstructive pulmonary disease
por: Serban, K.A., et al.
Publicado: (2022)

Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?
por: McGee, Dawn, et al.
Publicado: (2010)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

Alpha-1 Antitrypsin Deficiency: The Learning Goes On
por: Stockley, Robert. A.
Publicado: (2020)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
por: O'Brien, Michael E, et al.
Publicado: (2020)

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
por: McElvaney, Oliver J., et al.
Publicado: (2022)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19
por: Bai, Xiyuan, et al.
Publicado: (2021)

There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements
por: Stockley, James A, et al.
Publicado: (2021)

The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency
por: Tejwani, Vickram, et al.
Publicado: (2021)

Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence
por: Bai, Xiyuan, et al.
Publicado: (2023)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody
por: Tan, Lu, et al.
Publicado: (2015)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
por: Hawkins, Padraig, et al.
Publicado: (2021)

Physical Activity, Exercise Capacity and Sedentary Behavior in People with Alpha-1 Antitrypsin Deficiency: A Scoping Review
por: O’Shea, Orlagh, et al.
Publicado: (2023)

New Patient-Centric Approaches to the Management of Alpha-1 Antitrypsin Deficiency
por: Chorostowska-Wynimko, Joanna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_56jvlsto6sc032e55cmk9h4una